Frontlight ResearchEarly access
Taking people in NetherlandsPhase 1
Early study of AXN-027 in adults with chronic pain, epilepsy and related nerve disorders
Tests AXN-027 in adults with chronic pain or hard-to-treat epilepsy.
Key facts
- Who runs it
- Axonis Therapeutics Inc.
- Where
- Leiden, NetherlandsSee the site
- Trial code
- Registry title
- Three-part PK and PD study of AXN-027
- Status
- Recruiting
- Phase
- Phase 1
- People taking part
- 64 people, planned
- Started
- 29 Jun 2026
- Expected to end
- 31 Dec 2026
- Type of study
- Interventional
- Record updated
- 4 September 2026
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults aged 18 to 64 years. Healthy volunteers can join. The study looks at the drug AXN-027 in three parts.
- Age
- 18 to 64 years
- Sex
- All sexes can join.
Check if you might fit
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 64 years old?
Where in Netherlands
- Centre for Human Drug ResearchLeiden, NetherlandsTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record
Print a page for my doctorData and sources
- Registry record
- Listed on the EU's official list of trials (CTIS).
- Plain-language title
- Early study of AXN-027 in adults with chronic pain, epilepsy and related nerve disordersGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 9 November 2026.
- Fit questions
- Built from 2025-524019-35-00, who can take part
- Record updated
- 4 September 2026